![Todd Bazemore](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Todd Bazemore
Directeur/Membre du Conseil chez
PULMATRIX, INC.
Fortune : 647 $ au 31/05/2026
Profil
Todd Bazemore is President, Chief Executive Officer & Director at Airna, Inc. since 2026.
Mr. Bazemore is Independent Director at Pulmatrix, Inc. since 2020.
Former positions include Director at Kala Bio, Inc. from 2025 to 2026; Vice President-Managed Markets at Sumitomo Pharma America, Inc. from 2012 to 2013; Chief Commercial Officer & Executive Vice President at Dyax Corp.
from 2014 to 2016; Chief Operating Officer & Executive Vice President at Santhera Pharmaceuticals Holding AG from 2016 to 2017; and Chief Operating Officer & Executive Vice President at Santhera Pharmaceuticals (USA), Inc. from 2016 to 2017.
Education includes undergraduate studies at the University of Massachusetts Lowell.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 29/12/2025 | 290 ( 0% ) | 647 $ | 31/05/2026 | |
PULMATRIX INC -.--% | 23/02/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Todd Bazemore
| Sociétés | Poste | Début |
|---|---|---|
| PULMATRIX, INC. | Directeur/Membre du Conseil | 01/10/2020 |
Airna, Inc.
 Airna, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of RNA editing therapeutics | Directeur Général | 02/06/2026 |
Anciens postes connus de Todd Bazemore
| Sociétés | Poste | Fin |
|---|---|---|
| KALA BIO, INC. | Directeur Général | 23/11/2025 |
| SANTHERA PHARMACEUTICALS HOLDING AG | Directeur des opérations | 01/11/2017 |
Santhera Pharmaceuticals (USA), Inc.
 Santhera Pharmaceuticals (USA), Inc. Pharmaceuticals: MajorHealth Technology Develops and wholesales medicines for other diseases with high unmet medical needs | Directeur des opérations | 01/11/2017 |
| DYAX CORP. | Corporate Officer/Principal | 22/01/2016 |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Corporate Officer/Principal | 01/09/2013 |
Formation de Todd Bazemore
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
30
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Health Technology |
Dyax Corp.
 Dyax Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of novel biotherapeutics | Health Technology |
Kala Bio, Inc.
 Kala Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company developing mesenchymal stem cell secretive (MSC-S) therapies | Health Technology |
Santhera Pharmaceuticals Holding AG
 Santhera Pharmaceuticals Holding AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of neuromuscular diseases | Health Technology |
University of Massachusetts Lowell
 University of Massachusetts Lowell Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pulmatrix, Inc.
 Pulmatrix, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for pulmonary disease | Health Technology |
Santhera Pharmaceuticals (USA), Inc.
Santhera Pharmaceuticals (USA), Inc. Pharmaceuticals: MajorHealth Technology Develops and wholesales medicines for other diseases with high unmet medical needs | Health Technology |
Airna, Inc.
Airna, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of RNA editing therapeutics | Commercial Services |
